Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic
Conditions
Interventions
investigational material(s)
Generic name etc : AZD9150
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material
Sponsors
AstraZeneca
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Histologically or cytologically confirmed HCC (with the exception of fibrolamellar carcinoma or mixed variants of HCC with fibrolamellar histology OR clinically diagnosed HCC for patients with difficulty in obtaining histological diagnosis) -Relapsed, refractory, intolerant or unlikely to benefit from sorafenib (for example due to comorbidity) -Metastatic or locally advanced meeting ANY of the criteria below: -HCC not suitable to receive local therapy -Disease recurred or was refractory to last therapy (local or systemic) -Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 8 weeks Aged at 18 years. Patient from Japan and Taiwan aged at least 20 years.
Exclusion criteria
Exclusion criteria: -More than 2 prior systemic treatments for HCC -Prior grade 3 hematologic toxicity related to treatment with a JAK or STAT3 inhibitor -Presence of hepatic encephalopathy within 4 weeks of 1st dose -Uncontrolled massive ascites -High likelihood of bleeding
Outcome results
None listed